We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Oscar Health, Inc. (OSCR) Outpaced the Stock Market Today
Read MoreHide Full Article
Oscar Health, Inc. (OSCR - Free Report) ended the recent trading session at $18.46, demonstrating a +2.96% change from the preceding day's closing price. This change outpaced the S&P 500's 1.02% gain on the day. On the other hand, the Dow registered a gain of 1.62%, and the technology-centric Nasdaq increased by 0.89%.
Shares of the company have appreciated by 52.86% over the course of the past month, outperforming the Finance sector's gain of 7.2%, and the S&P 500's gain of 12.23%.
Analysts and investors alike will be keeping a close eye on the performance of Oscar Health, Inc. in its upcoming earnings disclosure. The company's earnings report is set to go public on May 6, 2026. It is anticipated that the company will report an EPS of $1.21, marking a 31.52% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $4.89 billion, reflecting a 60.62% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $0.2 per share and revenue of $18.91 billion, which would represent changes of +111.83% and +61.62%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Oscar Health, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Oscar Health, Inc. currently has a Zacks Rank of #3 (Hold).
In the context of valuation, Oscar Health, Inc. is at present trading with a Forward P/E ratio of 88.18. This valuation marks a premium compared to its industry average Forward P/E of 9.52.
The Insurance - Multi line industry is part of the Finance sector. With its current Zacks Industry Rank of 144, this industry ranks in the bottom 41% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
Why Oscar Health, Inc. (OSCR) Outpaced the Stock Market Today
Oscar Health, Inc. (OSCR - Free Report) ended the recent trading session at $18.46, demonstrating a +2.96% change from the preceding day's closing price. This change outpaced the S&P 500's 1.02% gain on the day. On the other hand, the Dow registered a gain of 1.62%, and the technology-centric Nasdaq increased by 0.89%.
Shares of the company have appreciated by 52.86% over the course of the past month, outperforming the Finance sector's gain of 7.2%, and the S&P 500's gain of 12.23%.
Analysts and investors alike will be keeping a close eye on the performance of Oscar Health, Inc. in its upcoming earnings disclosure. The company's earnings report is set to go public on May 6, 2026. It is anticipated that the company will report an EPS of $1.21, marking a 31.52% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $4.89 billion, reflecting a 60.62% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $0.2 per share and revenue of $18.91 billion, which would represent changes of +111.83% and +61.62%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Oscar Health, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Oscar Health, Inc. currently has a Zacks Rank of #3 (Hold).
In the context of valuation, Oscar Health, Inc. is at present trading with a Forward P/E ratio of 88.18. This valuation marks a premium compared to its industry average Forward P/E of 9.52.
The Insurance - Multi line industry is part of the Finance sector. With its current Zacks Industry Rank of 144, this industry ranks in the bottom 41% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.